Copnat-N 0.05% (Ointment)
Medicine Details
| Category | Details |
|---|---|
| Generic | Clobetasol propionate |
| Company | Renata limited |
| Also available as |
Indications
- Psoriasis (excluding widespread plaque psoriasis)
- Recalcitrant dermatoses
- Lichen planus
- Discoid lupus erythematosus
- Other skin conditions which do not respond satisfactorily to less potent steroids
Composition
- Clobetasol Propionate Cream: Each gram cream contains Clobetasol Propionate BP 0.5 mg (0.05% w/w)
- Clobetasol Propionate Ointment: Each gram ointment contains Clobetasol Propionate BP 0.5 mg (0.05% w/w)
- Clobetasol Propionate Scalp Application: Each gram lotion contains Clobetasol Propionate BP 0.5 mg (0.05% w/w)
- Clobetasol Propionate Shampoo: Each gram shampoo contains Clobetasol Propionate BP 0.5 mg (0.05% w/w)
- Clobetasol Propionate Lotion: Each gram lotion contains Clobetasol Propionate BP 0.5 mg (0.05% w/w)
- Clobetasol Propionate Spray: Each gram spray contains Clobetasol Propionate BP 0.5 mg (0.05% w/w)
Pharmacology
Clobetasol Propionate is a very potent topical corticosteroid. It has anti-inflammatory, antipruritic and vasoconstrictive properties. It shows anti-inflammatory activity via multiple mechanisms to inhibit late phase allergic reactions, decrease mast cell density, and inhibit cytokine production.
Dosage
- Apply a thin layer of Clobetasol Propionate Cream or Ointment to the affected skin areas twice daily for adults, elderly and children over 1 year
- The total dose of Clobetasol Propionate scalp solution should not exceed 50 ml weekly
- Clobetasol Propionate shampoo should be applied to the dry scalp once a day to the affected areas only
- Therapy with Clobetasol Scalp Solution should be discontinued if no response is noted after one week or as soon as the lesion heals
Administration
Route of administration: Cutaneous. Creams are especially appropriate for moist or weeping surfaces. Ointments are especially appropriate for dry, lichenified or scaly lesions.
Interaction
Co-administered drugs that can inhibit CYP3A4 (eg ritonavir, itraconazole) have been shown to inhibit the metabolism of corticosteroids leading to increased systemic exposure.
Contraindications
- Rosacea, acne vulgaris and perioral dermatitis
- Primary cutaneous viral infections (e.g. herpes simplex, chickenpox)
- Hypersensitivity to the preparation
- Not indicated in the treatment of primarily infected skin lesions caused by infection with fungi (e.g. candidiasis, tinea), or bacteria (e.g.impetigo): perianal and genital pruritus
- Dermatoses in children under one year of age, including dermatitis and napkin eruptions
Side Effects
- Prolonged use, or treatment of extensive areas can result in systemic absorption
- Local atrophic changes in the skin such as thinning, striae and dilatation of the superficial blood vessels
- Pustular form of psoriasis
- Pigmentation changes and hypertrichosis
- Hypersensitivity
Pregnancy & Lactation
Limited data in pregnant women. Caution should be exercised when administered to a nursing woman.
Precautions & Warnings
- Long-term continuous topical therapy should be avoided, particularly in infants and children
- Atrophic changes may occur after prolonged treatment with potent topical corticosteroids, especially on the face
- Care is needed to ensure that the preparation does not enter the eye when applied to the eye lids
Use in Special Populations
Long-term continuous topical corticosteroid therapy should be avoided in infants and children under 12 years of age
Overdose Effects
Chronic over-dosage may lead to hypercortisolism
Therapeutic Class
Other Topical corticosteroids
Storage Conditions
Keep below 30°C temperature, protected from light and moisture. Do not freeze. Keep out of the reach of children